Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/3/2008

This analysis showed that Multaq(R) (dronedarone) decreased the risk of stroke by 34% in patient with atrial fibrillation or atrial flutter already

adequately treated by antithrombotic therapy

BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCall/ -- The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany. Previous results from the landmark ATHENA study have shown that the investigational medicine Multaq(R) (dronedarone) on top of standard therapy decreased the combined primary endpoint of the risk of cardiovascular hospitalizations or death from any cause by a statistically significant 24% (p=0.00000002) as compared to placebo.

The ATHENA stroke post-hoc analysis on non-pre-specified secondary endpoints showed that Multaq(R) decreased the risk of stroke (ischemic or haemorrhagic) compared to placebo by 34% (46 vs 70 stroke events respectively; p=0.027) in atrial fibrillation / atrial flutter patients adequately treated by standard therapy including antithrombotics.

The significant reduction in stroke risk with Multaq(R) was incremental to background anti-thrombotic therapy like oral anticoagulants and / or anti-platelet agents. Similar to the ATHENA primary endpoint of CV hospitalizations or death, this effect appeared early and was maintained during the study follow-up (12 to 30 months).

"ATHENA is a landmark trial that will lead to a paradigm shift in the management of atrial fibrillation as it is the first time that an anti-arrhythmic drug has shown a significant impact on cardiovascular outcomes. As stroke is one of the leading complications of atrial fibrillation, and a major cause of death and long-term disability, these new results demonstrate the unique profile of Multaq(R) beyond its pure rhythm and rate-controlling effects," said Professor Stuart Connolly, Mc Master Uni
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
5. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Arpida Provides Further Comments on the Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Conn. , July 29, 2014 Numotion,s Board ... Mike Swinford will be the company,s new Chief ... highly successful 22-year career at GE where he worked primarily ... in annual revenue to over $5 billion. His most recent ... Services. "I am thrilled to join Numotion," ...
(Date:7/29/2014)... July 29, 2014 McGraw-Hill Education Professional, a ... science, technical, and medical communities, has announced the launch ... mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all iOS ... able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... DIEGO , July 29, 2014  Neurocrine Biosciences, ... the Company will report its second quarter 2014 financial ... 6, 2014.  Neurocrine will then host a live conference ... provide a Company update Thursday morning, August 7, 2014 ... Participants can access the live conference call ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... on the short arm of chromosome 6 (6p21.3), is a ... region is the human equivalent of the Major Histocompatibility Complex ... serve as the backbone of antigen presentation. The Class ... T-cells, are expressed by genes located in the HLA-A, -B ...
... the level of blood oxygenation can be an ... levels in the clinical setting is often desirable. ... sophisticated technology into easily used point-of-care devices, recent ... hemoglobin values., ,HemoCue, Inc., Lake Forest, Calif., says ...
Cached Medicine Technology:The Past, Present and Future of HLA Typing 2The Past, Present and Future of HLA Typing 3Hemoglobin Testing at the Point of Care 2Hemoglobin Testing at the Point of Care 3
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Decorative contact lenses may ... careful, they can cause serious eye damage. Decorative ... ophthalmologist, according to the U.S. Food and Drug Administration ... a valid prescription for these lenses and buy them ... spread the word about the potential health risks associated ...
(Date:7/29/2014)... Penn State College of Medicine, have jointly received ... health data research network., The Patient-Centered Outcomes Research ... Protection and Affordable Care Act, awarded the funds ... and Johns Hopkins University -- and each of ... come together to create a Clinical Data Research ...
(Date:7/29/2014)... July 29, 2014 July 29, 2014 – ... care, is proud to announce that it is a Bronze ... online video segments; Silverado Through a Child's Eye ... , In Silverado Through a Child's Eye , seven-year-old ... mom at Silverado Beverly Place, a memory care community in ...
(Date:7/29/2014)... BC (PRWEB) July 29, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical device ... will grow to over $8 billion by ... advancement, particularly in the transcatheter heart valve market, which ... (THVI) and the transcatheter mitral valve repair (TMVR) segments. ...
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 According ... marijuana in both the recreational and the medicinal sectors ... As legalized marijuana becomes more accepted in mainstream culture, ... drug aside from the traditional and more dangerous forms ... products are becoming quite the trend in legalized states ...
Breaking Medicine News(10 mins):Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:New network unites university health care research 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Marijuana Edibles Sales Show Growth in Market 2
... PARK, Fla., May 18 Transitions Optical, Inc.,today announced ... relevant information about eye health issues through SMS text ... have the option to subscribe to,receive valuable advice and ... eyes to see better today and in the future. ...
... Washinton DC (18 May 2009) Research published this week ... the annual costs of autism spectrum disorder (ASD) to be ... children with ASDs were estimated to be 2.7 billion per ... be presented at the Autism & Employment Workshop taking place ...
... MEI,s Broad Solution Offerings CORAL SPRINGS, Fla., May ... of The MEI Healthcare Group, announced today a ... GE ), a leading provider of healthcare technology. ... customers the option of MEI,s broad solutions, including ...
... by Shire to Patients Taking Lialda(R) (mesalamine) or Pentasa(R) ... Lost Their Jobs in 2009PHILADELPHIA, May 18 Shire ... global specialty biopharmaceutical company, is responding to the needs ... and prescribed gastrointestinal (GI) medications from Shire by expanding ...
... season; experts less sure about global outlook , , MONDAY, May ... raising critical questions about the timing of bringing a new ... the people who need it. , If vaccine manufacturers shift ... seasonal influenza vaccine, experts say. If they wait too long, ...
... blast injuries have become the signature injuries. These can ... damage to the visual system and the visual processing centers ... with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, on ... N.Y., May 18 The journey home is a bittersweet ...
Cached Medicine News:Health News:SMS Technology Places Eye Health Educational Information at Hispanics' Fingertips 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 3Health News:MEI Development Corporation and GE Healthcare Sign Strategic Agreement 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 3Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 4Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 5Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2
Multi-constituent normal and abnormal plasma controls for routine and specialty assays performed on the STA© family of hemostasis analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
Fructosamine Calibrator...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: